Novel, not adenylyl cyclase-coupled cannabinoid binding site in cerebellum of mice

Biochemical and Biophysical Research Communications

Volumn 292, Issue 1, 2002, Pages 231-235

  Monory, Krisztina ^a   Th Tzavara, Eleni ^a   Lexime, Jinette ^a   Hanoune, Jacques ^a   Ledent, Catherine ^b   Parmentier, Marc ^b   Borsodi, Anna ^c  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c INSTITUTE OF BIOCHEMISTRY   (Hungary)

Author keywords

Adenylyl cyclase; Cannabinoid receptor; CB1 knockout mice; Cerebellum; 35S GTP S binding

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ADENYLATE CYCLASE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DEXANABINOL; GUANOSINE 5' O (3 THIOTRIPHOSPHATE) S 35; RECEPTOR; RECEPTOR BLOCKING AGENT; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BINDING SITE; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; HIPPOCAMPUS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ANIMALIA; EPICOCCUM;

EID: 0036297517     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2002.6635     Document Type: Article

References (23)

1. Binding of aminoalkylindoles to noncannabinoid binding sites in NG108-15 cells
2. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide
3. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons
4. Anandamide and WIN55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes
5. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice
6. The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity
7. Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain
8. Characterization of Δ9-tetrahydro-cannabinol and anandamide antinociception in nonarthritic and arthritic rats
9. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice
10. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice
11. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: Evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain
12. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors
13. Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum
14. 9-tetrahydrocannabinol
15. Lysophospholipid receptors
16. 35S]thio)triphosphate binding stimulated by sphingosine 1-phosphate and lysophosphatic acid
17. Evidence for a new G-protein-coupled cannabinoid receptor in mouse brain
18. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine in C57/bl and CD-1 mice
19. Differential involvement of mu(1)-opioid receptors in endomorphin- and beta-endorphin-induced G-protein activation in the mouse pons/medulla
20. 35S]guanosine triphosphate gammaS binding in the brain of C57BL/6 and DBA/2 mice
21. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors
22. 9-THC-induced antinociception
23. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome